Omega, eyeing new uses for genome-tuning tech, taps Stanford to find ocular disease targets

www.fiercebiotech.com
2 min read
difficult
Having pulled off a $126 million IPO, the epigenomic specialist has teamed up with Stanford University School of Medicine to find eye disease targets.
Omega Therapeutics is branching out. Having pulled off a $126 million IPO, the epigenomic specialist has teamed up with Stanford University School of Medicine to find eye disease targets to hit with its technology.

Massachusetts-based Omega is focused on tuning the expression of genes by using mRNA-encoded therapeutics to target the control room of biology. The approach has manifested in a liver cancer candidate that Omega plans to take into the clinic next year and explorations of the application of the technology in other therapeutic areas, including corneal regeneration.

Omega is stepping up its eye disease ambitions in collaboration with the ophthalmology department at Stanford. Albert Wu, M.D.,…
Nick Paul Taylor
Read full article